Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Inclusion Criteria: * Subjects with 7.0%≤HbA1c≤10.0% at screening * Subjects treated with 1,000mg/day or higher dose of metformin for at least 8 weeks prior to screening * Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening * Subject who is willing and able to provide informed consent indicating that they understand the purpose and procedures required for the study Exclusion Criteria: * Subjects with fasting plasma glucose≥240mg/dL at screening * Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * Subject with ALT and AST 3 times or higher than upper normal range * Subject with history of myocardial infarction, cerebral infarction within 3 months prior to screening